This is a systematic review of cost-effectiveness studies reporting cost-per-DALY averted from 2000 through 2015 conducted using the Global Health Cost-Effectiveness Analysis (GHCEA) Registry. Authors summarized descriptive characteristics on study methodology. They analyzed a) the types of costs included, b) study quality and c) the correlation between diseases researched and the burden of disease in different world regions. 479 cost-per-DALY averted studies were published from 2000 through 2015, with studies from Sub-Saharan Africa representing the largest portion of published studies. The disease areas most commonly studied were communicable, maternal, neonatal, and nutritional disorders (67%), followed by non-communicable diseases (28%). A high proportion of studies evaluated primary prevention strategies (59%). Pharmaceutical interventions were commonly assessed (32%) followed by immunizations (28%). Adherence to good practices for cost-effectiveness analysis varied considerably. Studies mainly included formal healthcare sector costs.
Neumann PJ, Thorat T, Zhong Y, Anderson J et al. Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. PLoS ONE 2016; 11 (12): e0168512. https://doi.org/10.1371/journal.pone.0168512